Trevi Therapeutics

US · TRVI #2810 by market cap Listed 2019

13.14 -0.04 -0.30%

Live - 5344 symbols - heartbeat 420s ago · 2026-10-08 04:33

Pre-market 13.39 +1.90%

After-hours 13.14 0.00%

Market cap: 1.87B
P/E (TTM): -37.54
P/B: 5.82
EPS: -0.32
Div yield: 0.00%
52W pos: 35%

Reader sentiment Are you bullish or bearish on TRVI?

Anonymous reader poll. Unscientific, not investment advice.

About Trevi Therapeutics

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Founded: 2011
CEO: Ms. Jennifer L. Good
Employees: 34
Headquarters: New Haven, Connecticut, United States of America
Fiscal year end: 12-31
Website: trevitherapeutics.com

Company profile

Exchange: US
Symbol: TRVI
Market-cap rank: #2810
Listing date: 2019-05-07
Market cap: 1.87B
Float cap: 1.55B
Shares out: 142.48M
Float shares: 118.32M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 04:33:25 · For reference only, not investment advice and not tailored to your situation.